Circulating tumor cells (CTCs) are suspected of predicting the prognosis of malignant tumor, but there are few relevant reports specific to esophageal squamous cell carcinoma (ESCC). This study investigated the clinical significance of CTCs in patients with ESCC.
Introduction
Esophageal carcinoma is a common and deadly cancer in China and ranked as the fourth cause of cancer-related deaths. Since the early symptoms of esophageal squamous cell carcinoma (ESCC) are often hard to recognize, patients are usually at an advanced stage at the initial diagnosis. Late treatment leads to a poor prognosis, with 5-year survival rates of only 15% to 25%. [1] [2] [3] A poor prognosis is usually due to recurrence and metastasis.
Clinically, a considerable number of early-stage ESCC patients do not have obvious metastasis, but die of early tumor recurrence and distant metastasis after radical surgery. [4] This suggests that the spread of cancer cells cannot be detected by conventional clinical or histopathological methods.
Circulating tumor cells (CTCs) are tumor cells that are released into the peripheral blood from the primary tumor or metastatic lesions, either spontaneously or due to surgery. [5] CTCs from various tumors have the potential to act as precursors of metastases, including esophageal cancer. [6, 7] Methods to detect CTCs in esophageal cancer are mainly the following: reverse transcription (RT)-PCR, the Celltracks AutoPrep system, and isolation by size of epithelial tumor cells (ISET). RT-PCR disrupts the cells and is not applicable to a small number of CTCs, and the Celltracks AutoPrep system is limited by its inability to detect nonepithelial CTCs, which leads to a low detection rate. Although ISET technology loses a few small CTCs (<8 mm diameter), the technique is simple, inexpensive, and capable of separating viable CTCs. Thus, ISET is an ideal technique to detect CTCs of esophageal cancer.
The detection of CTCs is important for guiding the treatment strategy, and has been confirmed for prognostic evaluation of breast, prostate, gastric cancer, and other common malignant tumors. [8] [9] [10] However, there are few studies regarding the clinical significance of CTCs in ESCC, and most relevant studies used the Celltracks AutoPrep system for evaluations.
The present study investigated the clinical significance of CTCs in patients with ESCC. ISET was to detect the CTCs of ESCC patients before treatment. [11] 2. Patients and methods
Patients
The Shandong Provincial Cancer Research Institute Ethics Committee approved this study. All the enrolled patients provided written consent.
The inclusion criteria of the present study were the following: age >18 years; histological diagnosis of ESCC; World Health Organization (WHO) performance status between 0 and 2; and, treated only once or were without treatment for at least 6 months. Patients with any of the following were excluded: a history of unrelated carcinoma in the preceding 5 years; a history of dermatologic disease; or cervical esophageal cancer.
From May to December 2014, a cohort of 60 consecutive patients with primary ESCC was studied, which constituted the same cohort of patients who participated in our previous study, [11] except for 1 patient who withdrew from this followup study by his own initiative. Of the 60 patients, 50 patients had undergone R0 resection and postoperative adjuvant radiotherapy or chemotherapy, and were analyzed as a subgroup (surgery + chemoradiotherapy). Excluded were the remaining 10 patients with distant organ metastatic lesions and treated only with radiotherapy and chemotherapy and without surgical resection.
CTC analysis
CTC analysis was completed in our previous study using the CTC BIOPSY system to detect peripheral blood CTCs in a cohort of 61 patients. [11] Because in the present study 1 patient did not meet the inclusion criteria and was excluded, only the data of the 60 remaining patients were used for further analysis. The ISET assay was performed as described by Vona et al. [12] The samples were processed on an automatic testing platform in accordance with the manufacturer's instructions. Five milliliters of whole blood were diluted up to 8 mL with buffer containing 0.2% formaldehyde, and filtered through a membrane with a pore size of 8 mm. The harvested CTCs and circulating tumor microemboli were stained with Romanowsky stain, air dried, mounted, and blindly reviewed independently by 3 senior cytopathologists.
The isolated cells were assigned as CTCs if there were ≥4 of any of the following morphological characteristics: atypical nucleus (irregular shape or presence of a nodular, lobulated contour); nuclear-cytoplasmic ratio >0.8; nuclear long diameter >18 mm; hyperchromatic nuclei and nonhomogeneous staining; thickened, sunken, wrinkled, and jagged nuclear membrane; presence of nuclear chromatin side-shift or a large nucleoli or presence of abnormal mitotic figures; and presence of tumor cell aggregations, or circulating tumor microemboli.
In the 60 patients, 20 were determined as CTC-positive, a rate of 33.3%.
Clinical follow-up
The 60 patients with ESCC were followed for at least 2 years. ESCC progression, and times of recurrence, death, and diseasefree survival were recorded.
Progression-free survival (PFS) was defined as the time from the onset of CTCs testing to CT progression or patient death. If the patient was lost to follow-up, or at the end of follow-up ESCC had not progressed, then this was recorded as a delete value. When a patient was not rehospitalized after discharge and the telephone follow-up was not answered by patients or their relatives, the patient's initial hospitalization time was also taken as a PFS deletion. Overall survival was analyzed when patients were followed for 3 to 5 years.
Statistical analysis
All statistical analyses were performed using Statistical Package for Social Sciences software (SPSS version 22.0). Continuous variables were analyzed by t test and expressed as mean ± standard deviation. The chi-squared analysis or Fisher exact test was used to explore any correlation between CTC and clinicopathological variables. Kaplan-Meier survival curves were then used to describe the survival distributions of patients with different levels of CTCs. The log-rank test was used to analyze the survival data and calculate the P value. For the multivariate analysis, the Cox regression model was used. The results are presented as hazard ratio (HR) with 95% confidence interval (CI), that is, a multivariate analysis with stepwise regression. Correlations among the number of CTCs, the 2-year PFS, and Table 2 Presence of CTCs in the study population of 60 ESCC patients by clinicopathological characteristics. Han et al. Medicine (2019) 98:6 www.md-journal.com TNM staging were analyzed by Spearman method. P < .05 was considered statistically significant.
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Patient characteristics
The sixty patients (53 men, 7 women; 62.2 ± 7.2 years, range 49-78 years) with ESCC were recruited from May to December 2014 ( Table 1) . All of the patients were being treated for the first time or had experienced a minimum of 6 months without treatment.
The 60 patients were treated with chemotherapy, with or without surgery. Among them, a subgroup of 50 patients, who had undergone R0 resection and postoperative adjuvant radiotherapy or chemotherapy (surgery + therapy), were analyzed separately to control for variations in the treatments. The clinical manifestations of the patients (Table 1) were investigated, including the following: age, gender, duration of alcohol consumption, routine blood analysis, serum carcinoembryonic antigen (CEA) levels, WHO performance status, primary tumor location, tumor size, differentiation, lymph node metastasis, venous invasion, and stage.
Association between CTC and clinicopathological characteristics
In the total of 60 patients, the presence of CTCs was significantly associated with clinical stages (I-IIIB cf. IIIC-IV P = .01) of the cancer (Table 2) . CTCs were not significantly associated with patient age, gender, median alcohol consumption, platelet, neutrophil/lymphocyte (N/L) ratio, serum CEA, or WHO performance status. Moreover, CTCs were not correlated with pathological features such as tumor location, tumor size, grade of differentiation, tumor depth, lymph node metastasis, or lymphatic or venous invasion.
In the subgroup of 50 surgically treated patients, the presence of CTCs was significantly associated with platelet (P = .026) and clinical stages (I-IIIB cf. IIIC-IV P = .034; Table 3 ). CTCs were not significantly associated with age, gender, duration of alcohol consumption, neutrophil-to-lymphocyte ratio, serum CEA, or WHO performance status. CTCs were also not significantly associated with pathological features such as tumor location, tumor size, grade of differentiation, tumor depth, lymph node metastasis, or lymphatic or venous invasion. 
Association between CTC count and survival time
The median survival time of the 60 patients was 21 months. The number of CTCs was associated with PFS ( Fig. 1) . PFS was significantly shorter for patients with CTCs > 0 compared with patients with CTC = 0; CTCs > 1 compared with CTCs 1; and CTCs > 2 compared with CTCs 2 (median survival time: 9 cf. 7 months). In the group of 50 surgically treated patients, PFS decreased as the CTC count increased (P = .031) from 0 to 1, to ≥2 (Fig. 2D) .
The 60 patients were further divided into 4 groups according to the presence of CTCs and treatment (Fig. 3A) : CTC + with surgery; CTC -with surgery; CTC + with chemoradiotherapy; and CTC -with chemoradiotherapy. The comparative analysis showed that the PFS of the CTC -with surgery group was significantly longer than that of the other 3 groups (P = .001).
The 60 patients were also stratified into 4 groups based on the presence of CTCs and clinical stage (Fig. 3B) : CTC + and I-IIIB; CTC -and I-IIIB; CTC + and IIIC-IV; and CTC -and IIIC-IV. The PFS of patients in the CTC -and I-IIIB group was significantly longer than that of the other 3 groups (P = .006).
In the 60 patients, the univariate Cox regression analyses showed that the following were not significantly associated with PFS (Table 4) : age, gender, duration of alcohol consumption, platelet, neutrophil-to-lymphocyte ratio, serum CEA, WHO performance status, clinical stage, tumor location, grade of differentiation, tumor size, tumor depth, lymph node metastasis, and lymphatic or venous invasion. Conversely, CTCs > 2 was an independent prognostic marker for PFS (P = .008, HR 3.88; 95% CI 1.42-10.56). In addition, the risk of tumor recurrence was 2.3-fold higher in patients in whom CTCs were detected, compared with patients without CTCs (P = .036, HR 2.34, 95% CI 1.06-5.17).
The multivariate Cox regression analysis showed that patients with CTCs > 2 had significantly shorter PFS than those patients with CTCs 2 (P = .003, HR 5.63, 95% CI 1.77-17.887). Moreover, tumor location and grade of differentiation were independent prognostic markers for PFS (P < .05).
In the 50 surgical patients ( (2019) 98:6 www.md-journal.com preoperative presence of CTCs was significantly associated with a shorter PFS (P < .05).
Association between CTC count and TNM staging
Spearman rank correlation analysis showed that there was a correlation between the number of CTCs and T stage (r = 0.26, P = .043; Table 6 ); but no significant correlations were found between the number of CTCs and N stage (r = -0.037, P = .78; Table 7 ), or M stage (r = 0.19, P = .15; Table 8 ).
Associations among CTC count, TNM staging, and survival times
Of the 60 patients enrolled in this study, 12 patients were lost. Spearman rank correlation analysis showed that there was a negative correlation between the number of CTCs and PFS in the remaining 48 ESCC patients (r = -0.342, P = .017; Table 6 ); but no significant correlation between the number of CTCs and PFS was found when patients were stratified as II/III/IVI-IIIB/IIIC-IV/ I-II/III-IV stages (Table 6 ). CI = confidence interval, CTC = circulating tumor cell, PFS = progression free survival.
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In the 50 surgically treated patients stratified as stage II or I-IIIB or T3 and T3 + T4, the PFS of the patients with CTCs > 1 or CTCs > 2 was significantly shorter than that of patients with CTCs 1 or CTCs 2, respectively (P < .05; Tables 7 and 8 ). In stage III and T3 + T4 groups, the PFS of patients with CTCs > 0 was significantly shorter than that of the patients with CTCs = 0 (P < .05). Table 5 Univariate and multivariate analyses of progress-free survival in the 50 patients. 
Discussion
In this study, CTCs were detected in ESCC by using ISET technology, and were found to be associated with the number of platelets, ESCC staging, and patient's PFS. These results indicate that CTCs are independent prognostic indicators of patient clinical outcomes in ESCC.
CTCs detection in ESCC patients
Methods to detect CTCs in esophageal cancer are mainly RT-PCR, the Celltracks AutoPrep system, and ISET technology. In the present study, among 61 ESCC patients, CTCs were detected in 20 patients via the ISET method, a rate of 32.8%. Whereas, in the same patient cohort as our previous study, [11] CTCs were detected in only 1.6% when tested using the Celltracks AutoPrep system. This strongly indicates that the ISET method is more sensitive than the Celltracks AutoPrep. The greater sensitivity of ISET for detecting CTCs compared with the Celltracks AutoPrep system was also observed by Khoja et al [13] in patients with pancreatic cancer. The difference in the sensitivity of the 2 methods may be because the Celltracks AutoPrep system only detects epithelial CTCs, and misses mesenchymal CTCs. [14] In other studies, ISET was also found to be a better method for detection of esophageal cancer CTCs compared with RT-PCR or the Celltracks AutoPrep system. [15, 16] The high detection of CTCs in ESCC patients may explain the clinical observation that many patients with early-stage ESCC, in whom traditional detection methods found no signs of distant metastasis, soon died of tumor recurrence and metastasis, due to micrometastases from the spread of CTCs. [4] 
CTCs are prognostic of clinical outcomes of ESCC patients
Although the TNM staging system can predict the prognosis of cancer patients and guide clinicians to choose a treatment strategy, combining it with the CTCs count will be more effective. [17, 18] The positive association between CTCs count and ESCC clinical stage observed in the present study is in accord with previous observations that CTCs correlated with tumor differentiation, T stage, lymph node micrometastasis, and pathological stage. [19, 20] Our observation of an association between CTCs and the number of platelets is in agreement with the finding that platelets facilitate the generation of CTCs, and protect them from various host attacks, such as immune assaults, apoptosis, and shear stress. [21] Platelets also regulate the intravasation/extravasation of CTCs, and promote the survival of CTCs in the bloodstream. [22] The negative correlation found between PFS and CTCs in the ESCC patients of the present study was also found in patients with breast, pancreatic, or prostate cancer. [22] [23] [24] All these results indicate that CTCs are prognostic indicators of disease progress and poor clinical outcomes in ESCC patients.
Conclusion
This study is the first to show that the CTC, detected by ISET, is an independent and prognostic indicator of patients' outcome in ESCC. CTCs in patients with ESCC may lead to micrometastases that cannot be detected by traditional examination methods. CTCs detected by ISET technology may be used as prognostic indicators of disease progress and clinical outcomes in ESCC. 
